Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | HPGD | P15428 | 3/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.61 |
| ▸ | ALB | P02768 | 1/20 | 0.55 |
| ▸ | MMP2 | P08253 | 1/20 | 0.55 |
| ▸ | HNF4A | P41235 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | HMGB1 | P09429 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | LDHA | P00338 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA4 | P22748 | 2/20 | 0.46 |
| ▸ | CA7 | P43166 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | CA6 | P23280 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9109 | 0.98 | ALDH1A1 (0.63) | ALDH1A1KDM4EHPGDHSD17B10ALB | |
| SCHEMBL29633266 | 0.98 | ALDH1A1 (0.63) | ALDH1A1KDM4EHPGDHSD17B10ALB | |
| SCHEMBL4098212 | 0.96 | ALDH1A1 (0.61) | ALDH1A1KDM4EHPGDHSD17B10ALB | |
| Water SCHEMBL7762373 | 0.96 | ALDH1A1 (0.61) | ALDH1A1KDM4EHPGDHSD17B10ALB | |
| SCHEMBL17076506 | 0.96 | ALDH1A1 (0.61) | ALDH1A1KDM4EHPGDHSD17B10ALB | |
| Water SCHEMBL10709467 | 0.96 | ALDH1A1 (0.61) | ALDH1A1KDM4EHPGDHSD17B10ALB | |
| SCHEMBL17200169 | 0.96 | ALDH1A1 (0.61) | ALDH1A1KDM4EHPGDHSD17B10ALB | |
| Ammonia Solution, Strong SCHEMBL7767435 | 0.96 | ALDH1A1 (0.61) | ALDH1A1KDM4EHPGDHSD17B10ALB | |
| SCHEMBL3332893 | 0.96 | ALDH1A1 (0.61) | ALDH1A1KDM4EHPGDHSD17B10ALB | |
| Bicarbonate SCHEMBL3689372 | 0.94 | ALDH1A1 (0.59) | ALDH1A1KDM4EHPGDHSD17B10ALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226084-A9 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-07-11 | — | — | US | disclosed |
| US-20240131017-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-04-25 | — | — | US | disclosed |
| EP-4356912-A2 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | Techfields Pharma Co., Ltd. (CN) | 2024-04-24 | — | — | EP | disclosed |
| US-20240115562-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-04-11 | — | — | US | disclosed |
| US-11857545-B2 | High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-01-02 | — | — | US | disclosed |
| EP-2849738-B1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO LTD (CN) | 2023-12-06 | — | — | EP | disclosed |
| US-11813256-B2 | High penetration prodrug compositions and pharmaceutical compositon thereof for treatment of pulmonary conditions | PREMIER RESEARCH INTERNATIONAL, LLC | 2023-11-14 | — | — | US | disclosed |
| CN-116898848-A | High penetration prodrug compositions and pharmaceutical compositions for treating pulmonary diseases | 苏州泰飞尔医药有限公司 | 2023-10-20 | — | — | CN | disclosed |
| CN-107929743-B | High penetration prodrug compositions and pharmaceutical compositions for treating pulmonary diseases | 苏州泰飞尔医药有限公司 | 2023-09-01 | — | — | CN | disclosed |
| US-20230233516-A1 | HIGH PENETRATION COMPOSITIONS AND THEIR APPLICATIONS | TECHFIELDS PHARMA CO., LTD (CN) | 2023-07-27 | — | — | US | disclosed |
| US-20210353579-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | TECHFIELDS PHARMA CO LTD (CN) | 2021-11-18 | — | — | US | disclosed |
| US-20190142818-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOISITON THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD | 2019-05-16 | — | — | US | disclosed |
| US-9872846-B2 | High penetration compositions and uses thereof | TECHFIELDS PHARMA CO., LTD. (CN) | 2018-01-23 | — | — | US | disclosed |
| US-20170209585-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | TECHFIELDS PHARMA CO LTD (CN) | 2017-07-27 | — | — | US | disclosed |
| US-20170209404-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | PREMIER RESEARCH INTERNATIONAL, LLC | 2017-07-27 | — | — | US | disclosed |
| EP-2849738-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | Techfields Pharma Co., Ltd. (CN) | 2015-03-25 | — | — | EP | disclosed |
| US-20150072961-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | PREMIER RESEARCH INTERNATIONAL, LLC | 2015-03-12 | — | — | US | disclosed |
| WO-2013170655-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2013-11-21 | — | — | WO | disclosed |
| US-20110269689-A1 | HIGH PENETRATION COMPOSITIONS AND THEIR APPLICATIONS | PREMIER RESEARCH INTERNATIONAL, LLC | 2011-11-03 | — | — | US | disclosed |
| US-20090238763-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | TECHFIELDS PHARMA CO., LTD. (CN) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226084-A9 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | HRH4, HCAR2, PAH | CA2 943/4885ALDH1A1 1724/4885KDM4E 3941/4885 |
| US-11813256-B2 | High penetration prodrug compositions and pharmaceutical compositon thereof for treatment of pulmonary conditions | CPA3, PAH, HCAR2 | CA2 658/4885ALDH1A1 2282/4885KDM4E 4020/4885 |
| US-20240115562-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | HRH4, HCAR2, PAH | CA2 943/4885ALDH1A1 1724/4885KDM4E 3941/4885 |
| US-20150072961-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | HRH4, HCAR2, PAH | CA2 943/4885ALDH1A1 1724/4885KDM4E 3941/4885 |
| US-20110269689-A1 | HIGH PENETRATION COMPOSITIONS AND THEIR APPLICATIONS | SLC19A1, HIRA, SLC43A1 | CA2 4516/4885ALDH1A1 829/4885KDM4E 4307/4885 |
| US-20240131017-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | HRH4, HCAR2, PAH | CA2 943/4885ALDH1A1 1724/4885KDM4E 3941/4885 |
| US-20170209404-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | HPGDS, PTGIS, PTGES | CA2 2613/4885ALDH1A1 1790/4885KDM4E 4795/4885 |
| US-20210353579-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | HPGDS, PTGIS, PTGES | CA2 2613/4885ALDH1A1 1790/4885KDM4E 4795/4885 |
| US-20170209585-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | HPGDS, PTGIS, PTGES | CA2 2613/4885ALDH1A1 1790/4885KDM4E 4795/4885 |
| US-11857545-B2 | High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions | HRH4, HCAR2, PAH | CA2 943/4885ALDH1A1 1724/4885KDM4E 3941/4885 |
| US-20230233516-A1 | HIGH PENETRATION COMPOSITIONS AND THEIR APPLICATIONS | SLC5A7, SLC19A1, SLC43A1 | CA2 3495/4885ALDH1A1 2302/4885KDM4E 2401/4885 |
| US-20190142818-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOISITON THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | CPA3, HCAR2, HRH4 | CA2 381/4885ALDH1A1 2258/4885KDM4E 4181/4885 |
| US-20090238763-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | HPGDS, PTGIS, PTGES | CA2 2613/4885ALDH1A1 1790/4885KDM4E 4795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.